Acquisition pricing is currently fixed at $995,000 USD firm for the complete domain bundle (AITrials.com, AITrials.ai, AITrials.app). Current pricing remains available through December 31, 2026. The acquisition price is subject to an upward adjustment to $1,995,000 USD firm anytime during the first quarter of 2027, without further notice.
Where AI-powered clinical trials are born, built, and executed under one roof.
AI-enabled clinical trials are moving toward real-time operations, shared infrastructure, agentic automation, and cross-company platforms. AITrials.com is the one-of-one .com that sits directly on top of that category.
One price. Three extensions. Immediate transfer upon cleared payment.
AITrials.ai and AITrials.app are included in the acquisition and transferred as part of the complete bundle at no additional cost. The transaction is processed through the standard Afternic / GoDaddy domain acquisition process, providing secure transfer protection for both parties.
It cannot be recreated. It cannot be copied. Once another organization owns it, it is permanently off the market — for every competitor, for every decade that follows.
The clinical trials industry has undergone a decade of consistent language compression. The category started as AI-enabled clinical trials. It shortened to AI clinical trials. The natural shorthand in use today — in regulatory documents, investor decks, conference agendas, and platform names — is AI trials.
AITrials.com is the natural destination of that compression. It is the cleanest possible digital identity for the entire category: exact match, only eight letters before .com, no hyphen, no invented brand, no filler words, immediate meaning in every language.
This is not a speculative name. This is the category name. There is a fundamental difference between a domain that describes a product and a domain that is the category. AITrials.com is the latter. It was registered in 2016 — before most organizations understood what AI-enabled clinical trials would become — and it has sat at the top of the category vocabulary ever since.
For the right buyer — a CRO building its AI platform, a pharma company launching its clinical AI initiative, a consortium establishing neutral infrastructure, or a software firm staking its category claim — the acquisition cost is a one-time event. The value compounds for every year the name is owned. The cost of a competitor owning it is not fixed. It grows every year they do.
Exact-match .com
The enterprise-standard extension, not a workaround
Eight letters before .com
Among the shortest meaningful category .coms available
Registered since 2016
Established long before the category became competitive
No hyphen. No filler.
Clean, neutral, immediate — no invented syllables
Globally usable
Understood without translation across every major market
Permanently scarce
Once acquired, no equivalent replacement exists
The U.S. government has committed to AI-native trial infrastructure at scale. These are not pilot programs. This is structural transformation — and it is happening now.
SURPASS — Simulation-augmented, Real-time Platform Adaptive Seamless Trials — was launched September 30, 2026 by HHS and ARPA-H. The five-year, government-funded initiative is designed to compress trial timelines from over a decade to under four years through predictive computational models, real-time data analysis, and agentic automation.
SURPASS introduces three technical pillars: a Phaseless Design Engine (digital twins replacing traditional phase structures), a Continuous Inference Engine (real-time adaptive trial decisions), and an Agentic Operations Layer (automated trial startup, data collection, and arm onboarding).
On September 15, 2026, FDA launched the Expedited IND Pilot under HHS Operation TrialBlazer — a program designed to accelerate first-in-human trial startup by pairing drug sponsors with Qualified Research Institutions (QRIs) for rolling pre-IND component review.
Applications are open through October 30, 2026. FDA intends to select an initial cohort of 8–10 sponsor-QRI pairs. The program is part of a broader effort to cut first-in-human trial initiation times from up to two years to a fraction of that, positioning the U.S. competitively against accelerating global rivals.
STACK is a companion initiative to SURPASS that uses AI to accelerate clinical site activation — converting research-naïve facilities into active, capable trial sites at a scale and speed not previously possible through conventional methods.
STACK addresses one of the persistent bottlenecks in clinical-trial execution: the limited pool of qualified, activated sites available to sponsors and CROs. By applying AI to site readiness assessment, training, and activation workflows, STACK expands the operational reach of the entire clinical-trial ecosystem.
COMMONS is the shared data architecture component of the SURPASS program ecosystem. It is building a national-scale, privacy-by-design data infrastructure providing regulatory-grade data access for predictive modeling, adaptive trial design, and real-world evidence generation across the U.S. clinical-trial system.
COMMONS is designed to be shared infrastructure — not owned by any single sponsor, CRO, or technology vendor. It represents a structural shift toward collective, interoperable, real-time clinical data access as a foundation for AI-native trial operations.
The industry is building platforms, ecosystems, and shared infrastructure that span multiple organizations. That creates a naming problem AITrials.com uniquely solves.
Large clinical-trial initiatives increasingly involve multiple organizations working in concert: sponsor companies, CROs, academic research centers, technology vendors, regulatory agencies, and data infrastructure providers. SURPASS is a government-funded example. COMMONS is a shared-infrastructure example. The Operation TrialBlazer pilot is a collaborative-pairing example. Across the industry, multi-party clinical platforms and data consortiums are becoming the operating model.
This creates a recurring branding problem that no corporate name cleanly solves: whose name sits at the top when multiple companies are involved? A sponsor’s corporate name implies ownership and excludes peers. A CRO’s name implies service relationship and limits the platform’s neutral credibility. A technology vendor’s name implies tool rather than infrastructure. Any company-specific name at the top of a multi-party initiative immediately politicizes the initiative for every participant below it.
AITrials.com solves this directly. It does not belong linguistically to any CRO, any pharma company, any software vendor, or any single institution. It describes the category — not the company. That neutrality is not incidental. It is structurally valuable in proportion to how many organizations a platform, consortium, or initiative needs to unite. The larger and more multi-party the initiative, the more valuable the neutral category name above it becomes.
This is especially relevant for joint ventures between multiple pharma companies, CRO alliances, public-private partnerships, cross-company AI platforms, shared data infrastructure programs, and industry consortiums — exactly the initiatives that SURPASS, COMMONS, and Operation TrialBlazer represent at the government level.
“A neutral category name can unite multiple organizations under a single digital identity without forcing every participant underneath one company’s corporate brand. That is a structural advantage no invented brand name can replicate.”
AITrials.com is not just a website name. The three-extension bundle owns the cleanest digital identity for the entire category — and the category has many dimensions. Any of the following is a legitimate, immediately deployable use of the acquisition.
The value is not only in owning three URLs. The value is owning the cleanest, most complete digital identity for the entire category — across every extension a competitor could use to build credibility alongside you.
The acquisition question is not only what AITrials.com can do for you. It is what happens if your biggest competitor owns it instead.
When a prospect, investor, regulator, or partner types “AI trials” — your competitor’s platform is the category front door. Every search, every conference mention, every publication reference routes through their brand.
A competitor who owns AITrials.com controls the platform narrative for the entire category. Every product launch, consortium announcement, and infrastructure initiative sits under a domain name your team can never use.
If the industry moves toward multi-party consortiums and shared infrastructure, a competitor who owns the neutral category name owns the umbrella. Every partner in every consortium they lead comes in through their front door, not yours.
Once acquired, AITrials.com is off the market permanently. There is no equivalent replacement. Responding to a competitor who owns the category .com is not a brand problem — it is a strategic position problem with no clean fix.
Your competitor’s campaign URL is the category name itself. Every conference banner, every sponsored session, every industry email references the domain your audience mentally associates with AI trials as a concept.
Domain authority, brand recognition, and category association compound over time. A competitor who owns AITrials.com in 2026 is harder to displace in 2031 and effectively impossible to displace in 2036. The cost of inaction rises every year.
The acquisition of AITrials.com is not only about what the buyer can build. It is equally about what competitors can no longer do. Once acquired, no competitor can own this exact category .com, build the neutral umbrella around it, control the category front door, or deploy it as the dominant brand above a multi-party platform or consortium. That is competitive optionality — and defensive ownership — at the category level. The question for any serious buyer is not whether the asset has value. The question is whether they can afford to let someone else own it.
AITrials.com communicates the category in eight letters. For pharmaceutical AI teams, CROs, and clinical trial technology companies, this domain makes the positioning immediately legible to sponsors, sites, regulators, and investors — with zero explanation and zero brand education required.
A clean .com matters in pharmaceutical, clinical, and regulatory contexts in a way that .ai, .io, or invented domains do not. AITrials.com carries the credibility benchmark that regulated-industry buyers, research institutions, and government partners expect for serious infrastructure.
Organizations launching a new AI clinical-trial platform or initiative typically spend years building category association with an invented brand name. AITrials.com delivers that association on day one — the name itself is the category. No brand-building runway required.
The bundle delivers AITrials.com, AITrials.ai, and AITrials.app — every major extension a competitor could use to build credibility alongside the buyer, closed in a single acquisition. No competitor can park a matching extension or build a parallel brand under the same category name.
FDA’s Expedited IND Pilot application window closes October 30, 2026. ARPA-H SURPASS launched September 30, 2026. The organizations establishing their AI clinical-trials brand and infrastructure identity in Q4 2026 will own the category conversation for the decade ahead. The window to acquire AITrials.com before a competitor does is measured in months, not years.
Verified recent sales establish the market for premium AI domain assets. AITrials.com is a .com — structurally more valuable than a .ai alone — offered as a three-extension bundle covering a specific, regulated, high-spend category.
| Domain | Sale Price | Date | Extension | Strategic Note |
|---|---|---|---|---|
| AI.com | $70,000,000 | Apr 2025 | .com | Category-defining two-letter .com — establishes that category ownership has no ceiling |
| Bot.ai | $1,200,000 | Feb 2026 | .ai only | First .ai publicly confirmed to break $1M — single word, no .com, no bundle |
| Fin.ai | $1,000,000 | 2025 | .ai only | Single-word vertical .ai — finance sector, no .com, no bundle |
| Wisdom.ai | $750,000 | 2025 | .ai only | Single-word abstract .ai — held the .ai record before Bot.ai, no vertical specificity |
| Law.ai | $350,000 | 2025 | .ai only | Single-word vertical .ai — legal sector, no .com, no bundle |
| AITrials.com + .ai + .app | $995,000 | Available Now | .com + .ai + .app | Three-extension bundle · Exact-match category name · Regulated, high-spend sector |
The distinction that matters for strategic buyers: Every .ai domain listed above sold as a single extension with no matching .com and no bundle. Bot.ai sold for $1.2M as a single .ai alone. AITrials.com is a .com — the enterprise standard in healthcare and life sciences — bundled with both matching AI and app extensions, covering a specific regulated category where the next generation of clinical-trial infrastructure spend is actively flowing. A conservative strategic valuation range for the full AITrials.com bundle is USD $1.2M to USD $1.8M. The current USD $995,000 Buy It Now price is below the estimated strategic replacement value for the right buyer. Note: comparable sales sourced from Sedo, NameBio, and DN Journal public records.
How to frame this acquisition for internal budget approval
AITrials.com is currently listed at USD $995,000 for the full acquisition bundle: AITrials.com, AITrials.ai, and AITrials.app.
For a strategic buyer, the value is not based on domain traffic or existing web presence. The value is category control, brand clarity, immediate market authority, complete extension protection, and the ability to own the exact language of AI-enabled clinical trials — the phrase regulators, sponsors, and trial operators are already using.
Comparable AI and premium category domains confirm that strategic buyers consistently pay seven figures for names that remove branding friction and deliver immediate category authority. A conservative strategic valuation range for the full AITrials.com bundle is USD $1.2M to USD $1.8M. That places the current USD $995,000 Buy It Now price below the estimated strategic replacement value for the right CRO, pharma AI team, clinical trial software company, or life sciences AI platform.
The complete three-extension bundle transfers immediately upon cleared payment. Domain acquisitions of this type are typically recorded as intangible assets on the balance sheet, not expensed as marketing costs. The acquisition cost is fixed. The cost of a competitor owning this name compounds every year they hold it.
Review the strategic category fit, buyer use cases, acquisition structure, bundle details, comparable domain sales, and pricing logic for the AITrials.com, AITrials.ai, and AITrials.app package.
Domain Bundle Included in This Acquisition
AITrials.ai and AITrials.app are included in the acquisition and transferred as part of the complete bundle at no additional cost.
Acquisition Price: USD $995,000 — Buy It Now
All three domains transfer upon cleared payment and completion of standard Afternic / GoDaddy transfer requirements. There are no alternative pricing structures, financing arrangements, or installment options. The acquisition is a single, clean Buy It Now transaction.
Transaction handled through Afternic / GoDaddy — the standard domain acquisition process provides verified ownership transfer and secure transaction handling for both parties. Corporate due diligence is fully supported.
Yes. AITrials.com is available for acquisition through the official Afternic listing. The Buy It Now price is $995,000 for the complete three-extension bundle: AITrials.com, AITrials.ai, and AITrials.app. Visit the official listing through the acquisition buttons on this page.
The Buy It Now acquisition at USD $995,000 includes the complete three-extension bundle: AITrials.com, AITrials.ai, and AITrials.app. AITrials.ai and AITrials.app are included and transferred as part of the complete bundle at no additional cost. All three extensions transfer immediately upon cleared payment.
AITrials.com is positioned for pharmaceutical companies, Contract Research Organizations (CROs), clinical trial technology platforms, clinical data companies, clinical imaging AI firms, AI site-selection and patient-recruitment platforms, life sciences AI infrastructure companies, and organizations building or branding AI-enabled clinical trial initiatives, consortiums, or shared infrastructure programs.
No. There is one acquisition structure: Buy It Now at USD $995,000 for the complete bundle. There are no installment plans, financing arrangements, lease structures, or alternative payment terms available.
The acquisition is processed through the standard Afternic / GoDaddy domain acquisition process, providing secure, verified ownership transfer for both parties. Corporate due diligence is fully supported. All three domains transfer upon cleared payment and completion of standard transfer requirements.
Yes. Qualified buyers can work through Afternic broker communication for domain verification, ownership documentation, and corporate due diligence support.
Click any “Begin Acquisition,” “Acquire AITrials.com,” or “View Acquisition Details” button on this page. These route to the official Afternic listing where you can review the Buy It Now terms and begin the formal acquisition process.
The current USD $995,000 Buy It Now price is below the estimated strategic replacement value of USD $1.2M to $1.8M for the right buyer. The pricing reflects a single, clean acquisition rather than a protracted negotiation. For a qualified strategic buyer, the domain is available now at a price that reflects acquisition efficiency, not the category position it delivers.
Where AI-powered clinical trials are born, built, and executed under one roof.
ARPA-H SURPASS launched September 30, 2026. The FDA Expedited IND Pilot is accepting applications now. The clinical-trial AI infrastructure buildout is accelerating at a government-validated, multi-billion-dollar scale. The organizations that establish their category identity in Q4 2026 will own the category conversation for the decade ahead. AITrials.com is available today — at a price below its estimated strategic replacement value. Once another company acquires it, every competitor loses the option permanently.